Healthcare -
Biotechnology - NASDAQ - US
$ 166.01
-3.09 %
$ 4.78 B
Market Cap
55.15
P/E
1. INTRINSIC VALUE
Balance Sheet
Krystal Biotech, Inc.
| Current Assets | 742 M |
| Cash & Short-Term Investments | 598 M |
| Receivables | 105 M |
| Other Current Assets | 39.8 M |
| Non-Current Assets | 314 M |
| Long-Term Investments | 152 M |
| PP&E | 161 M |
| Other Non-Current Assets | 231 K |
| Current Liabilities | 102 M |
| Accounts Payable | 4.98 M |
| Short-Term Debt | 1.22 M |
| Other Current Liabilities | 95.8 M |
| Non-Current Liabilities | 7.46 M |
| Long-Term Debt | 6.04 M |
| Other Non-Current Liabilities | 1.42 M |
EFFICIENCY
Earnings Waterfall
Krystal Biotech, Inc.
| Revenue | 291 M |
| Cost Of Revenue | 20.1 M |
| Gross Profit | 270 M |
| Operating Expenses | 205 M |
| Operating Income | 65.7 M |
| Other Expenses | -23.5 M |
| Net Income | 89.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Krystal Biotech, Inc.
| Net Income | 89.2 M |
| Depreciation & Amortization | 6.71 M |
| Capital Expenditures | -4.24 M |
| Stock-Based Compensation | 49.1 M |
| Change in Working Capital | -14.5 M |
| Others | 52 M |
| Free Cash Flow | 119 M |
Wall Street Analysts Price Targets
Krystal Biotech, Inc.
Wall Street analysts predict an average 1-year price target for KRYS of $209 , with forecasts ranging from
a
low of
$204 to a high of $220 .
KRYS Lowest Price Target
Wall Street Target
204 USD
22.88%
KRYS Average Price Target
Wall Street Target
209 USD
25.75%
KRYS Highest Price Target
Wall Street Target
220 USD
32.52%
4. DIVIDEND
ANALYSIS
KRYS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Krystal Biotech, Inc.
Sold
0-3 MONTHS
17.9 M USD 3
3-6 MONTHS
16.5 M USD 2
6-9 MONTHS
19.8 M USD 2
9-12 MONTHS
20.9 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX®, one of the most widely recognized global brands. Mr. Forth has also served as a valuable contributor on Jeune's board of directors since February 2021.
globenewswire.com
- 3 days ago
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
zacks.com
- 3 days ago
Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK
Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation, potentially boosting its global market presence and valuation. Despite KRYS's premium valuation, its growth potential, strong financials, and first-mover advantage justify the market's appraisal, with a fair value estimate of $175-$185 per share. Key risks include regulatory setbacks, reimbursement issues, competition from Abeona's EB-101, and high operational expenses, which could impact short-term valuation and cash flow.
seekingalpha.com
- 2 weeks ago
Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
zacks.com
- 2 weeks ago
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
- 3 weeks ago
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
zacks.com
- 1 month ago
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
zacks.com
- 1 month ago
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
zacks.com
- 1 month ago
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA's) announcement that its Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the European Commission (EC) to approve VYJUVEK® (beremagene geperpavec-svdt, or B-VEC) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. The CHMP's positive opinion includes support for administration of VYJUVEK in either a health care setting (e.g.
globenewswire.com
- 1 month ago
Why Krystal Biotech (KRYS) Might be Well Poised for a Surge
Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
zacks.com
- 1 month ago
Why Krystal Biotech, Inc. (KRYS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
- 1 month ago
Krystal Biotech (KRYS) Upgraded to Buy: Here's What You Should Know
Krystal Biotech (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 1 month ago
8. Profile
Summary
Krystal Biotech, Inc. KRYS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 4.78 B
Dividend Yield
0.00%
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Contact
2100 Wharton Street, Pittsburgh, PA, 15203
https://www.krystalbio.com
IPO
Date
Sept. 20, 2017
Employees
275
Officers
Mr. Josh Suskin
Senior Director & Head of US Human Resources
Mr. John Karakkal
Vice President of North American Sales & Marketing
Ms. Jennifer McDonough
Senior Vice President of Patient Access, Analytics & Operations
Mr. Laurent Goux
Senior Vice President & GM of Europe
Mr. John Thomas
General Counsel & Corporate Secretary
Mr. David Chien
Senior Vice President of Clinical Development
Ms. Suma M. Krishnan
Founder, President of R&D and Director
Ms. Christine Wilson
Head of U.S. Sales & Marketing
Dr. Stephane Paquette Ph.D.
Vice President of Corporate Development
Mr. Krish S. Krishnan M.B.A., M.S.
Founder, Chairman, President & Chief Executive Officer